Alkermes ALKS Stock
Alkermes Price Chart
Alkermes ALKS Financial and Trading Overview
| Alkermes stock price | 46.03 USD |
| Previous Close | 46.11 USD |
| Open | 46.75 USD |
| Bid | 39.79 USD x 100 |
| Ask | 52.38 USD x 100 |
| Day's Range | 45.74 - 46.75 USD |
| 52 Week Range | 26.4 - 55.67 USD |
| Volume | 1.28M USD |
| Avg. Volume | 1.88M USD |
| Market Cap | 7.71B USD |
| Beta (5Y Monthly) | 0.26 |
| PE Ratio (TTM) | 120.97369 |
| EPS (TTM) | 0.38 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 56 USD |
ALKS Valuation Measures
| Enterprise Value | 8.63B USD |
| Trailing P/E | 120.97369 |
| Forward P/E | 25.144402 |
| PEG Ratio (5 yr expected) | 1.96 |
| Price/Sales (ttm) | 4.6245127 |
| Price/Book (mrq) | 4.258453 |
| Enterprise Value/Revenue | 5.174 |
| Enterprise Value/EBITDA | 30.281 |
Trading Information
Alkermes Stock Price History
| Beta (5Y Monthly) | 0.26 |
| 52-Week Change | 73.34% |
| S&P500 52-Week Change | 15.74% |
| 52 Week High | 55.67 USD |
| 52 Week Low | 26.4 USD |
| 50-Day Moving Average | 49.99 USD |
| 200-Day Moving Average | 38.05 USD |
ALKS Share Statistics
| Avg. Volume (3 month) | 1.88M USD |
| Avg. Daily Volume (10-Days) | 1.31M USD |
| Shares Outstanding | 167.76M |
| Float | 155.19M |
| Short Ratio | 10.71 |
| % Held by Insiders | 1.40% |
| % Held by Institutions | 108.05% |
| Shares Short | 14.72M |
| Short % of Float | 12.16% |
| Short % of Shares Outstanding | 8.76% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 2:1 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 3.96% |
| Operating Margin (ttm) | 15.49% |
| Gross Margin | 87.18% |
| EBITDA Margin | 17.08% |
Management Effectiveness
| Return on Assets (ttm) | 4.20% |
| Return on Equity (ttm) | 3.85% |
Income Statement
| Revenue (ttm) | 1.67B USD |
| Revenue Per Share (ttm) | 10.05 USD |
| Quarterly Revenue Growth (yoy) | 27.00% |
| Gross Profit (ttm) | 1.45B USD |
| EBITDA | 284.93M USD |
| Net Income Avi to Common (ttm) | 66.12M USD |
| Diluted EPS (ttm) | 0.38 |
| Quarterly Earnings Growth (yoy) | -99.40% |
Balance Sheet
| Total Cash (mrq) | 656.58M USD |
| Total Cash Per Share (mrq) | 3.91 USD |
| Total Debt (mrq) | 1.57B USD |
| Total Debt/Equity (mrq) | 86.95 USD |
| Current Ratio (mrq) | 2.3 |
| Book Value Per Share (mrq) | 10.795 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 251.18M USD |
| Levered Free Cash Flow (ttm) | 153.38M USD |
Profile of Alkermes
| Country | United States |
| State | N/A |
| City | Dublin |
| Address | Connaught House |
| ZIP | D04 C5Y6 |
| Phone | 353 1 772 8000 |
| Website | https://www.alkermes.com |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2050 |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Q&A For Alkermes Stock
What is a current ALKS stock price?
Alkermes ALKS stock price today per share is 46.03 USD.
How to purchase Alkermes stock?
You can buy ALKS shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Alkermes?
The stock symbol or ticker of Alkermes is ALKS.
Which industry does the Alkermes company belong to?
The Alkermes industry is Drug Manufacturers - Specialty & Generic.
How many shares does Alkermes have in circulation?
The max supply of Alkermes shares is 167.76M.
What is Alkermes Price to Earnings Ratio (PE Ratio)?
Alkermes PE Ratio is 121.13158000 now.
What was Alkermes earnings per share over the trailing 12 months (TTM)?
Alkermes EPS is 0.38 USD over the trailing 12 months.
Which sector does the Alkermes company belong to?
The Alkermes sector is Healthcare.
Alkermes ALKS included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
25981.57 USD — |
-0.78
|
7.02B USD — | 25943.31 USD — | 26172.12 USD — | — - | 7.02B USD — |
|
Dow Jones U.S. Biotechnology In
DJUSBT
US
|
3591.58 USD — |
+0.65
|
96.65M USD — | 3541.87 USD — | 3599.27 USD — | — - | 96.65M USD — |
|
NYSE Arca Pharmaceutical Index
DRG
US
|
1231.67 USD — |
-0.29
|
— — | 1222.45 USD — | 1237.36 USD — | — - | — — |
|
US Tech Biotechnology Total Retu
XNBI
US
|
7526.03 USD — |
-1.41
|
— — | 7475.1 USD — | 7620.74 USD — | — - | — — |
|
US Tech US Smart Pharmaceuticals
NQSSPH
US
|
2154.63 USD — |
-0.44
|
— — | 2139.56 USD — | 2162.04 USD — | — - | — — |
|
US Tech AlphaDEX Multi Cap Growt
NQDXUSMLTCG
US
|
3822.15 USD — |
-0.84
|
— — | 3811.78 USD — | 3857.32 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6887.9 USD — |
-1.46
|
— — | 6841.27 USD — | 6974.62 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1294.5 USD — |
-1.07
|
— — | 1285.37 USD — | 1305.11 USD — | — - | — — |
|
US Tech Composite Total Return
XCMP
US
|
32087.45 USD — |
-0.78
|
— — | 32040.2 USD — | 32322.77 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12769.21 USD — |
-0.76
|
— — | 12750.37 USD — | 12862.09 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
